4.7 Article

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis

期刊

FRONTIERS IN PHARMACOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.776969

关键词

beta-lactam; cephalosporin; avibactam; optimal dose; multidrug resistant tuberculosis

资金

  1. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [1R01HD099756-02]
  2. University of Texas System STARS award [250439/39411]
  3. department of Pulmonary Immunology, UT Health Science Center at Tyler, Texas [423500/14000]
  4. NIH/NIAID [R01AI079497, R56AI111985]

向作者/读者索取更多资源

Cefazolin-avibactam combination has shown efficacy against MDR-TB and drug susceptible TB strains in children through PK/PD principles. The optimal dosing strategy was determined based on age-specific CFR and Mtb susceptibility breakpoint, highlighting the potential of repurposing cefazolin for pediatric TB treatment.
Background: While tuberculosis (TB) is curable and preventable, the most effective first-line antibiotics cannot kill multi-drug resistant (MDR) Mycobacterium tuberculosis (Mtb). Therefore, effective drugs are needed to combat MDR-TB, especially in children. Our objective was to repurpose cefazolin for MDR-TB treatment in children using principles of pharmacokinetic/pharmacodynamics (PK/PD). Methods: Cefazolin minimum inhibitory concentration (MIC) was identified in 17 clinical Mtb strains, with and without combination of the beta-lactamase inhibitor, avibactam. Next, dose-ranging studies were performed using the intracellular hollow fiber model of TB (HFS-TB) to identify the optimal cefazolin exposure. Monte Carlo experiments were then performed in 10,000 children for optimal dose identification based on cumulative fraction of response (CFR) and Mtb susceptibility breakpoint in three age-groups. Results: Avibactam reduced the cefazolin MICs by five tube dilutions. Cefazolin-avibactam demonstrated maximal kill of 4.85 log(10) CFU/mL in the intracellular HFS-TB over 28 days. The % time above MIC associated with maximal effect (EC80) was 46.76% (95% confidence interval: 43.04-50.49%) of dosing interval. For 100 mg/kg once or twice daily, the CFR was 8.46 and 61.39% in children <3 years with disseminated TB, 9.70 and 84.07% for 3-5 years-old children, and 17.20 and 76.13% for 12-15 years-old children. The PK/PD-derived susceptibility breakpoint was dose dependent at 1-2 mg/L. Conclusion: Cefazolin-avibactam combination demonstrates efficacy against both drug susceptible and MDR-TB clinical strains in the HFS-TB and could potentially be used to treat children with tuberculosis. Clinical studies are warranted to validate our findings.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据